INS and type 2 diabetes mellitus: Metformin, a biguanide synthetized at the beginning of the past century, is nowadays the first-line pharmacotherapy for type 2 diabetes mellitus (T2DM) due to its remarkable capability to control plasma glucose levels, primarily via decreased hepatic glucose production/output associated with enhanced insulin sensitivity and increased peripheral glucose uptake [1,2].